RESEARCH TRIANGLE PARK, N.C. – April 23, 2009 – Quintiles was named by industry decision-makers as the most favored contract research organization (CRO), according to two recently released independent surveys. Quintiles ranked number one across a range of service and reputation attributes, from breadth of service through to therapeutic expertise.

Results from the fourth annual “CRO Industry Update,” an independent survey of executives at pharmaceutical and biotech companies conducted by William Blair & Company in conjunction with CenterWatch, cited Quintiles as the most frequently mentioned favorite CRO. For “Preferred CRO Ranking by Quality,” Quintiles was rated number one, with three times as many votes as the second place competitor.

In a separate industry survey, respondents rated Quintiles number one in 17 of 18 major attributes, often by wide margins. The independently conducted “The 2009 CRO Quality Benchmarking Report” by Industry Standard Research (ISR) asked 160 pharmaceutical and biotechnology executives – all with recent experience working with outsourced development providers – to rate their perceptions of 13 CROs and three non-traditional functional service providers.

Asked which product development service provider they would prefer to use if the decision were completely up to them, 27% of ISR survey respondents said Quintiles – more than double the next closest competitor, at 13%. Quintiles was also rated highest for “Overall Value,” at 14%, with the next closest competitor named by 9% of respondents.

Asked by ISR to name the product development service provider that has “done the best job of differentiating itself,” almost one in five respondents (18%) named Quintiles. The percentages of all other companies named ranged from zero to 6%.

“These reports are tangible evidence that we’re adding value to our customers’ products and portfolios in ways our competitors cannot,” said Jeff Thomis, President of Quintiles’ Global Core Clinical group. “Customers are seeing the difference in using Quintiles. It shows in the quality of our work force, in our consistently excellent service delivery, and in the ability of our world-class medical and scientific experts to offer unique insights to speed up decision making in drug development.”

More detail on the ISR results is available in the table below.

Quintiles Ratings by ISR Survey Respondents
CRO Service Attributes Rank Percent Selecting Quintiles No. 1
Breadth of Services No. 1 43% (Closest competitor = 8%)
Global Footprint No. 1 48% (8%)
Local Market / Regulatory Knowledge No. 1 28% (9%)
Industry Reputation No. 1 28% (9%)
Therapeutic Expertise of Project Team No. 1 24% (9%)
Efficient Site Start-Up No. 1 20% (9%)

The ISR report is available at

Quintiles Transnational Corp. helps bring new medicines to market and peak sales faster by providing innovative, high-quality development, partnerships and commercialization solutions to the pharmaceutical and biotechnology industries. With more than 22,000 employees and offices in more than 50 countries, Quintiles is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company’s Web site at